Review
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S et al.
ReviewThe Lancet. Neurology2021
Research Facts
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S et al.
Review · Moderate · 2021
Findings

PubMed study on Mannan in cosmetics/dermatology

Design
Review
Evidence
Moderate
Journal
The Lancet. Neurology